Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoposide plus G-CSF versus G-CSF only with CD34+ count-adapted plerixafor mobilization in multiple myeloma
KCT0006245Phase 3Completed
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Jun 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of etoposide, filgrastim, plerixafor in multiple myeloma (MM), sponsored by Seoul St. Mary's Hospital. Started Jun 2021; status: completed.
02
Drugs
etoposidefilgrastimplerixafor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0006245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006245.